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Abstract
Objective: To describe patient antiretroviral therapy (cART) outcomes associated with intensive decentralization of services
in a rural HIV program in Malawi.
Methods: Longitudinal analysis of data from HIV-infected patients starting cART between August 2001 and December 2008
and of a cross-sectional immunovirological assessment conducted 12 (62) months after therapy start. One-year mortality,
lost to follow-up, and attrition (deaths and lost to follow-up) rates were estimated with exact Poisson 95% confidence
intervals (CI) by type of care delivery and year of initiation. Association of virological suppression (,50 copies/mL) and
immunological success (CD4 gain $100 cells/mL), with type of care was investigated using multiple logistic regression.
Results: During the study period, 4322 cART patients received centralized care and 11,090 decentralized care. At therapy
start, patients treated in decentralized health facilities had higher median CD4 count levels (167 vs. 130 cell/mL, P,0.0001)
than other patients. Two years after cART start, program attrition was lower in decentralized than centralized facilities (9.9
per 100 person-years, 95% CI: 9.5–10.4 vs. 20.8 per 100 person-years, 95% CI: 19.7–22.0). One year after treatment start,
differences in immunological success (adjusted OR=1.23, 95% CI: 0.83–1.83), and viral suppression (adjusted OR=0.80, 95%
CI: 0.56–1.14) between patients followed at centralized and decentralized facilities were not statistically significant.
Conclusions: In rural Malawi, 1- and 2-year program attrition was lower in decentralized than in centralized health facilities
and no statistically significant differences in one-year immunovirological outcomes were observed between the two health
care levels. Longer follow-up is needed to confirm these results.
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Introduction
In sub-Saharan Africa, approximately 5,200 people became
newly infected with HIV each day in 2008, and 3835 died daily
from AIDS-related conditions [1]. Malawi bears one of the largest
HIV-related health burdens in the world. An estimated 1 million
people are living with HIV/AIDS, and approximately 84,000 new
infections and 68,000 HIV-related deaths occur annually [2–4].
The Malawian Ministry of Health adopted an ambitious public
health approach for combined antiretroviral therapy (cART) scale-
up in 2004 [2,5,6]. At the end of 2008, it was estimated that 56%
of people in urgent need for ART were receiving treatment [7,8]
and a total of 147,479 individuals were alive and receiving therapy
in the country [9]. Over 80% of the Malawian population lives in
rural settings [10], but most patients access treatment through
major urban sites or district hospitals.
The effectiveness of cART in terms of mortality reduction at
both population [11] and individual level [12,13] has been well
documented. However, important challenges limit scaling-up of
care, including difficult access of rural populations to centralized
care, and shortage of health workers. With only one doctor per
100,000 people [14,15], health care in Malawi is generally
provided by clinical officers and, as the HIV case load increases,
delegation of tasks to medical assistants and nurses is implemented.
In the Chiradzulu district, located in Southern Malawi, 1 in 4
adults are estimated to be living with HIV infection. In 2003
decentralized HIV care started being provided by mobile health
teams every 2 weeks in 10 peripheral health facilities [16]. By mid-
2004 one quarter of all cART initiations in the district occurred in
decentralized health facilities. The size of the mobile teams and the
number of days when HIV care services were provided increased
over time. In 2007 nurses working at the health centers were
trained to initiate cART and to monitor the clinical evolution of
HIV-infected patients, further accelerating the scale-up of HIV
care provision. The feasibility and safety of wide scale-up of HIV
care through decentralization to primary health centers, and task-
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[12,17–21]. Results from effectiveness evaluations are inconsistent
[22,23].
Here we describe temporal trends in patient characteristics at
cART start and compare outcomes in HIV-infected patients
receiving decentralized versus centralized care in Chiradzulu,
Malawi.
Materials and Methods
Study setting and participants
The Chiradzulu HIV program was established in 1996 as a
collaboration between the Ministry of Health of Malawi and
Me ´decins Sans Frontie `res (MSF). Free provision of cART at the
district hospital started in August 2001 [24,25]. To increase access
to HIV care in this large and populated district (.310,000 people)
with an estimated HIV prevalence of 20% in 2007, decentraliza-
tion of care to 10 peripheral health facilities started in 2003 using
mobile medical teams. Health service decentralization included
cART initiation and clinical follow-up of patients by clinical
officers. As of May 2007, nurses and medical assistants began
initiating therapy to adults. During follow-up, patients could access
HIV care in any of the health facilities of the district. Lay
community workers carried out HIV testing, daily registration and
scheduling of patients and routinely traced defaulters within 2 days
of missing their clinic appointments. Information about patient
death was collected through several mechanisms including reports
from family members at the health facilities, tracing by lay
community workers and verification of inpatient records. All
services related to HIV care, including laboratory testing,
provision of cART, management of opportunistic infections and
hospitalization, were free.
Eligibility criteria for cART initiation followed World Health
Organization (WHO) treatment guidelines: CD4 cell count ,200
cells/mL( ,250 since January 2007), clinical stage 4 irrespective of
CD4 cell count, and since January 2007, clinical stage 3
irrespective of CD4 cell count [25]. After cART start, and once
the patient’s health stabilized, clinical visits were scheduled at a
maximum of every 3 months. Group and individual counseling,
including adherence support, was provided by peer workers and
trained counselors. Routine CD4 count testing was performed
before and every 12 months after starting cART. Viral load testing
was only done when treatment failure was suspected.
Study design and data collection
First, a retrospective cohort analysis of monitoring data from
patients starting cART between August 2001 and December 2008
at the district hospital and at 10 rural health centers was
conducted. Sociodemographic, clinical, and treatment information
were routinely recorded on the patient files. Carbon-copied
duplicate forms were then sent to the hospital for data entry in an
electronic database (FUCHIA; Epicentre, Paris, France) and
record filing. Standard data consistency checks (e.g. consistency
between key dates such as dates of enrolment, cART start or date
of death) and verifications (e.g. regular cross-verification of paper
forms and laboratory information against the information entered
in the database) were routinely done on and off site.
Second, a cross-sectional survey was carried out in February–
July 2009 to determine immunovirological outcomes among
patients receiving cART for 1262 months. A random selection
of 702 eligible patients was invited to participate in the evaluation
(312 in centralized and 390 in decentralized care). The sample size
was estimated to detect a 10% difference in virological failure
between patients receiving centralized versus decentralized care,
assuming a significance level of 5% and 80% power. Fifty-two
(7.4%) women were excluded due to current pregnancy or
breastfeeding, 9 (1.3%) had died, 3 (0.4%) had been transferred
outside the program, 13 (1.8%) were lost to follow-up and 7 (1.0%)
declined participation. Table S1 compares the characteristics of
patients who were included and excluded from the study. A total
of 618 patients were enrolled and participated in the survey.
An independent clinical team scheduled appointments for the
study patients, obtained informed consent, and conducted the
cross-sectional evaluation. Physical examination by clinicians,
including assessment of cART adherence during the previous
month using a 10-point visual analogue scale, and blood draws for
laboratory testing, were performed at the facilities. Results were
recorded on standardized questionnaires. Data were double-
entered into a Microsoft Access database.
Blood specimens were collected and labeled. CD4 cell counts
were quantified using semi-automated machines (Cyflow counter,
Partec, Mu ¨nster, Germany) at the laboratory of the Chiradzulu
district hospital. Plasma samples were stored at -20uC and
transported to the DREAM Laboratory (Blantyre, Malawi) weekly
for viral load quantification with the VERSANT HIV-1 RNA
bDNA assay (version 3.0, Siemens Healthcare Diagnostics,
Deerfield, IL, USA; lower limit of detection was 50 copies/mL).
Statistical analysis
Retrospective cohort analysis. We used individual patient
monitoring data to compare patient characteristics at cART start
by calendar period of cART initiation (2001–2002, 2003–2004,
2005–2006, 2007–2008) and type of care delivery (centralized or
decentralized). Type of care was defined as patient attendance to
the district hospital or to health centers, respectively, for at least
90% of all consultations since cART initiation. Characteristics
between the two care groups were compared using chi-squared
tests or Fisher exact tests for categorical and Wilcoxon rank sum
tests for continuous variables.
Time of follow-up for each patient started at the time of cART
initiation and was censored at the earliest of the following dates:
death, transfer outside the program, last clinic visit or 2 years.
One-year mortality, lost to follow-up, and attrition (deaths and lost
to follow-up) rates were estimated with exact Poisson 95%
confidence intervals (CI). Lost to follow-up was defined as missing
a scheduled appointment by 2 months or more.
Cross-sectional survey. The proportions of patients includ-
ed in the cross-sectional evaluation with undetectable viral load,
virological failure (.5000 copies/mL), and CD4 cell counts ,200
cells/mL, and gains in CD4 counts since the start of therapy were
stratified according to the type of care received. In sensitivity
analyses, the rate of virological failure was estimated assuming
both, that patients who were alive and in care 12 months after
cART start but who did not participate in the cross-sectional study
had experienced the same rate of virological failure as patients
who participated in the evaluation; and that all patients who died
or were lost to follow-up between 6 and 12 months after cART
start had experienced virological failure. Patients who died or were
lost to follow-up within 6 months of therapy initiation were
excluded from this estimation because in WHO guidelines only
patients who receive cART for more than 6 months are considered
in the definition of treatment failure. Multiple logistic regression
was used to compare virological suppression (,50 copies/mL) and
immunological success (CD4 gain since treatment start $100
cells/mL) at 12 months of cART among patients aged 2 years or
more, and 5 years or more, respectively. Factors considered in
multivariable models were residence in the Chiradzulu district
(yes/no), sex, age in quartiles (#25, 26–35, 36–42, and $43 years),
Scale-Up and Decentralization of HIV Care
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2 for patients aged .18
year old, and equivalent age and sex specific BMI cut-off points for
the 2–18 year old group [26]), highest education level achieved
(none, primary, and high school or more), and adherence in last 4
weeks (,90%, 90% and 100%) at the time of the survey; and
record of history of cART use, CD4 cell count (#100, .100 cells/
mL, and missing) and clinical stage (1 or 2; and 3 or 4) at cART
start. The initial CD4 cell count was defined as the closest
recorded measurement to therapy start between 3 months before
and 1 month after this date.
All factors associated with a CD4 gain $100 cells/mL (or with
virological suppression) in univariable analyses (P,0.20) were
included in the corresponding multivariable models. Likelihood
ratio tests for associations across categories of variables were
calculated. Sensitivity analyses excluding observations with missing
CD4 cell count and clinical stage data (n=60) were also
performed. All data analyses were carried out using STATA
statistical software, version 11.2 (StataCorp, College Station, TX,
USA). Statistical significance was defined by two-sided P values of
,0.05.
Ethics
The study was approved by the National Health Science
Research Committee of Malawi. Written patient informed consent
was obtained from participants or from guardians of participants
for minors before participation in the cross-sectional survey.
Results
Patient characteristics by type of care delivery
A total of 17,699 patients started cART between August 1, 2001
and December 31, 2008. Of these, 4322 received centralized care,
and 11,090 decentralized care. The other 2287 patients who
received mixed care were excluded from the analysis. As scaling-
up through decentralization to peripheral health facilities progres-
sively evolved in the program, the number of cART initiations
increased, with a steep raise observed during the 2007–2008
period (Figure 1). During the period 2001–2002, 78.5% of
initiations took place at centralized level. By the end of 2008,
86.5% of cART initiations occurred in health centers. The
number of therapy initiations in decentralized facilities greatly
increased over time, from 56 in 2001–2002 to 3,598 in 2008. In
contrast, the number of patients who were started on cART at
hospital level, increased until the end of 2004, and then started
declining slowly over time.
In each time period, higher proportions of men were initiated
on cART in centralized than in decentralized facilities (P,0.001,
2003–2008), and median age was similar in patients who received
centralized or decentralized care (Table 1). As the program scaled
up and cART became more accessible, an increasing number of
patients started cART with less advanced HIV disease. The initial
median CD4 cell count increased from 122 cells/mL in 2001–2002
to 149 in 2007–2008 at centralized level, and from 93 cells/mLi n
2001–2002 to 176 in 2007–2008 at decentralized level. Median
CD4 cell count increases were higher in patients receiving
decentralized care than in those treated in centralized health
facilities (P,0.001 after 2002).
Similarly, the proportion of patients in advanced clinical stage
decreased over the study period from 79.2% in 2001–2002 to
69.4% in 2007–2008 at centralized level, and from 82.7% in
2001–2002 to 46.1% in 2007–2008 at decentralized level. At
cART start and after the year 2002, the proportions of patients
with clinical stage 1 or 2 and with high median CD4 cell counts
were higher in patients treated in decentralized facilities than in
those who received centralized care.
Mortality and program attrition by type of care delivery
Overall rates of mortality and program attrition among patients
who initiated therapy were 11.5 per 100 person-years (95% CI:
10.9–12.1) and 19.5 per 100 person-years (95% CI: 18.5–20.2) at 1
year of cART start and 6.9 per 100 person-years (95% CI: 6.6–
7.3) and 12.6 per 100 person-years (95% CI: 12.2–13.1) at 2 years,
respectively. As the program scaled up, patient attrition and
mortality decreased in both centralized and decentralized health
facilities (Figure 2).
During the first year of cART use, mortality and attrition rates
were higher in patients treated at central level than in those treated
in decentralized health centers (Figure 3). At 6 months of cART
use, rates of mortality were 27.8 per 100 person-years (95% CI:
25.3–30.6) at centralized level, and 15.5 per 100 person-years
(95% CI: 14.4–16.7) at decentralized level. In the 6–12 month
period of cART use, mortality rates were 6.5 per 100 person-years
Figure 1. Trends in cART enrollment in centralized and decentralized sites, Chiradzulu, Malawi, 2001–2008.
doi:10.1371/journal.pone.0038044.g001
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years (95% CI: 2.9–3.9) at decentralized level.
Six-month rates of attrition were 47.2 per 100 person-years
(95% CI: 44.1–50.4) at central level, and 23.8 per 100 person-
years (95% CI: 22.5–25.1) at decentralized level; and 6–12 month
attrition rates were 13.8 per 100 person-years (95% CI: 12.1–15.7)
at central level, and 6.2 per 100 person-years (95% CI: 5.5–6.9) at
decentralized level.
One-year immunovirological outcomes and associated
risk factors
Six hundred and eighteen patients had immunovirological data
at 1 year of cART. Of them, 279 (45.2%) received centralized care
and 339 (54.8%) decentralized care.
Of the 584 patients older than 5 years old, 10 (3.8%) patients
who received centralized care and 3 (0.9%) treated in health
centers had CD4 counts ,100 cells/mL( P=0.02). Median CD4
cell gain in the same age group was higher in individuals followed
at decentralized health facilities than in those receiving centralized
care (+167 cells/mL vs. +145; P=0.03). After 1 year of therapy,
66.9% of patients had CD4 gains of 100 cells/mL or greater,
70.2% of decentralized and 62.7% of centralized patients. In
contrast, 57.8% of patients had undetectable viral load one year
after ART initiation, 56.6% of decentralized and 59.1% of
centralized patients. Only 35 (5.7%) patients had viral load .5000
copies/mL. In sensitivity analysis we estimated an overall failure
rate in the program of 9.4% (95% CI: 8.9–9.9%).
Although patients followed at decentralized level, were less likely
to achieve virological suppression after 1 year of therapy (adjusted
OR [aOR]=0.80, 95% CI: 0.56–1.14) and more likely to achieve
CD4 gains $100 cells/mL (aOR=1.23, 95% CI: 0.83–1.83), these
associations were not statistically significant (P=0.21, and 0.30,
respectively). Women (aOR=1.59, 95% CI: 1.08–2.34; P=0.02),
and patients with no history of ART use at therapy initiation
(aOR=2.99, 95% CI: 1.13–7.88; P=0.02) were more likely to
achieve CD4 gains $100 cells/mL after 1 year of cART (Table 2).
Older patients were more likely to be virologically suppressed after
cART start (aOR=1.84, 95% CI: 1.03–3.29 for the 36–42 year
group; and aOR=2.15, 95% CI: 1.22–3.81 for the $43 year
group, compared to patients aged #25 years). Sensitivity analyses
restricted to patients with complete CD4 count data showed
similar results (data not shown).
Figure 2. Evolution of mortality, lost to follow-up, and attrition 1 year after cART start.
doi:10.1371/journal.pone.0038044.g002
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Expanding access to cART is essential to reduce AIDS-related
mortality [27]. This study describes early therapy outcomes among
patients treated in a large rural HIV program where extensive
scale-up of care was achieved through both delegation of clinical
work to non-physician medical personnel and decentralization of
health services. Our findings suggest that decentralization of care
to primary health facilities is not only associated with increased
access to cART in terms of numbers of patients receiving therapy,
but also with earlier treatment start in the course of the disease and
lower program attrition. Furthermore, in this setting, we did not
observe statistical significant differences in immunological and
virological outcomes between patients who received decentralized
or centralized care after 1 year of cART.
In the Chiradzulu program access to HIV care improved over
time, as shown by the increase in the number of patients starting
cART and by both, the proportion of patients started on cART at
early stages of HIV disease (e.g. WHO clinical stage 1 or 2) and
patient median CD4 cell counts at central and decentralized levels.
Compared to patients who received decentralized care, those
treated at central level were more likely to be men and to be
severely immunosuppressed, but less likely to have low BMI at
therapy initiation. The higher median CD4 cell count observed in
patients who received centralized care could be explained by a
combination of the existence of in-patient care and a later
presentation of male patients compared to women [28].
Overall program attrition (combined mortality and lost to
follow-up) decreased over time and, despite the increasing number
of patients started and followed on therapy in decentralized health
facilities, this decrease was more important at decentralized care
level. After 1 year of cART, 83% of patients continued receiving
HIV care (79% after 2 years). These findings are comparable or
better than those reported in other African HIV programs,
including other MSF programs, where patients were primarily
treated in hospitals or urban locations [12,29–32]. They are also
similar to weighted mean rates estimated in a systematic review of
patient retention in sub-Saharan African HIV programs [33]. The
low attrition rate observed among decentralized patients in
Chiradzulu could be related to the reduction of patient travel
time and costs achieved through decentralization, both factors
identified as barriers to HIV care in previous studies [34,35], and/
or to the higher proportion of patients who were living outside the
Chiradzulu district at central level.
Figure 3. Evolution of rates of mortality, lost to follow-up, and attrition after cART initiation.
doi:10.1371/journal.pone.0038044.g003
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PLOS ONE | www.plosone.org 7 October 2012 | Volume 7 | Issue 10 | e38044Virological suppression 1 year after therapy start was observed
in 58% of patients. Although this figure is lower than the estimated
median proportion of patients virologically suppressed reported in
a recent systematic review including data from 29 HIV programs
in sub-Saharan Africa, it falls within the range of published
estimates (median across studies was 82%, range 51%–97%) [2].
While most studies conducted in sub-Saharan Africa have defined
virological suppression using a ,400 copies/mL threshold, in our
study we used a more conservative definition (threshold of ,50
copies/mL). In secondary analyses where viral suppression was
defined using the ,400 copies/mL definition, 86% of patients had
suppressed viral load, 299 (88%) in decentralized health facilities
and 234 (84%) at central level. These results are similar to those
recently reported in South Africa, Zambia, and Cameroon
[12,21,23,36–38]. The high proportion of patients with viral load
measurements between 50 and 400 copies/mL is surprising (29%
overall, 69 patients in centralized and 107 in decentralized health
facilities) and deserves further investigation. The evaluation of
long-term immunovirological patient outcomes in the program
could help to understand better the implications of this finding.
In our analysis women and patients who had no history of
cART use before enrolment in the HIV program of Chiradzulu
were more likely to have gains of CD4 counts $100 cells/mL and
virological suppression more likely to be observed in patients aged
35 years or more. Higher immune recovery was also reported in
previous studies [37,39–42]. In a recent analysis including 4 large
HIV programs in sub-Saharan Africa, we found higher immune
recovery in women than in men, estimated that sex differences
increased by an average of 20 CD4 cells per year in the first 6
years after cART start and also that the time needed to reach 500
cells/mL was shorter for women [42]. As in our analysis, similar
gains in CD4 cell counts but higher percentages of patients with
viral suppression were also reported in a matched case-control
study comparing immunovirological outcomes in older and
younger patient (101 patients aged 50–79 years and 202 aged
21–39 years old) in the United States [43].
The burden of HIV infection on health systems and service
providers in Malawi is overwhelming. The growing volume of
patients receiving cART and the effects on non-HIV related
services causes concern, raising questions about the most cost-
effective strategies to ensure access to cART while maintaining
acceptable treatment outcomes in HIV patients, and the optimal
achievable level of task delegation to less-qualified personnel.
Scarcity of qualified health care staff, limited access to laboratory
testing, unreliable water and electricity supply, and poor road
infrastructure are some of the challenges faced when HIV care is
provided in rural areas, where the majority of patients in this
population live. The decentralization of HIV care and cART
provision from central hospitals to rural decentralized health
facilities provides an opportunity for improved access. Wide
community uptake of cART services and delegation of clinical
tasks traditionally performed by physicians to well trained and
supervised non-physician health staff have contributed to the
achievements of the program.
The findings of this study need to be interpreted in light of some
limitations. First, the retrospective evaluation was based on
analysis of routine data, and, despite the mechanisms in place to
document mortality among patients (e.g. reporting by family and
community tracing workers), ascertainment of death was incom-
plete. Indeed, in a previous study in the same setting, we found
that 54% of adults started on cART and lost to follow-up were
dead [25]. Although we are likely to have underestimated
mortality in this analysis, we also reported program attrition,
defined as a combined endpoint of deaths and lost to follow-up
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than decentralized health facilities). Second, virological monitoring
was not routinely performed and immunovirological outcomes
were assessed in patients who were randomly selected among those
still receiving care in the program after 1 year of therapy.
However, the participation rate in the cross-sectional survey was
high (88%) and patients included and excluded from the study had
similar characteristics at cART start except for the slightly higher
proportion of patients with history of cART use and of women,
and the higher proportion of patients in clinical stage 3 or 4 among
patients not included in the assessment (Table S1). Third, the
proportion of patients achieving good immunovirological out-
comes might have been overestimated, since poorer outcomes are
expected to be found in patients with more advanced HIV disease,
which is the case for patients who died or were lost to follow-up
during the first months of therapy. Nevertheless, failure rates
derived from the sensitivity analysis estimated that only 9% of
patients treated in the program would be in virological failure after
receiving cART for one year. Fourth, this in an observational
study and patients were therefore not randomized to be followed
in decentralized or centralized health facilities. Although investi-
gation of risk factors in this large study was adjusted for a number
of major confounding factors, including year of cART start,
severity of HIV disease and patient adherence of therapy, residual
confounding could still be present. Finally, during the initial phase
of cART provision in the program, eligibility for therapy start was
primarily based on the clinical condition of the patient (e.g. WHO
clinical staging) instead of on the results of CD4 count testing.
CD4 cell count information was therefore not available for 9.7%
of patients included in the analysis. Nevertheless, sensitivity
analyses restricted to patients with complete data did not change
the conclusions of the analysis.
In conclusion, one-year and two-year HIV program attrition
was lower in decentralized than in centralized health facilities of
Malawi and no statistically significant differences in one-year
immunovirological outcomes were observed between the two
health care levels. Longer follow-up is needed to confirm these
favorable results. The value of using health care providers with less
formal training in rural settings remains an important area for
further investigation in rural African settings of high HIV
prevalence.
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